[{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-211","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-211","moa":"||BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":1,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Infusion","sponsorNew":"EsoBiotec \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ AstraZeneca"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EsoBiotec \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ Undisclosed"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EsoBiotec \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Dana-Farber Cancer Institute | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"CM-CS1 T Cell","moa":"CS1","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad Oncology \/ Dana-Farber Cancer Institute | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Celyad Oncology \/ Dana-Farber Cancer Institute | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Precirix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"131-I SGMIB Anti-HER2 VHH1","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precirix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Precirix \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"GLPG0187","moa":"Integrins (multiple)","graph1":"Oncology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Private Placement","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-101","moa":"NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Merck & Co"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CYAD-101","moa":"NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CYAD-101","moa":"NKG2 D activating NK receptor (KLRK1)","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celyad Oncology \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Celyad Oncology \/ Merck & Co"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-02","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"CYAD-02","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"DeuterOncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DO-2","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"DeuterOncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DeuterOncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"DeuterOncology \/ Undisclosed"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ECI-006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"eTheRNA immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eTheRNA immunotherapies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"eTheRNA immunotherapies \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"NKR-2 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"NKR-2 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad Oncology \/ Undisclosed"}]
Find Oncology Drugs in Phase I Clinical Development in BELGIUM
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
